Cargando…

Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies

Primary antibody deficiencies (PAD) represent a heterogeneous group of disorders, with common variable immunodeficiency being the most common with clinical significance. The main phenotypic defect resides in the inability of B cells to produce antibodies, and the cornerstone of therapy is immunoglob...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsinti, Gerasimina, Makris, Demosthenes, Germenis, Anastasios E., Speletas, Matthaios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695510/
https://www.ncbi.nlm.nih.gov/pubmed/33274244
http://dx.doi.org/10.1155/2020/8317671
_version_ 1783615204544741376
author Tsinti, Gerasimina
Makris, Demosthenes
Germenis, Anastasios E.
Speletas, Matthaios
author_facet Tsinti, Gerasimina
Makris, Demosthenes
Germenis, Anastasios E.
Speletas, Matthaios
author_sort Tsinti, Gerasimina
collection PubMed
description Primary antibody deficiencies (PAD) represent a heterogeneous group of disorders, with common variable immunodeficiency being the most common with clinical significance. The main phenotypic defect resides in the inability of B cells to produce antibodies, and the cornerstone of therapy is immunoglobulin replacement treatment in order to fight infections. However, the management of the other inflammatory manifestations is inadequate, reinforcing the hypothesis that a complex genetic background affecting additional cell populations, such as polymorphonuclear cells (PMN) and monocytes, influences the expression of the clinical phenotype of the disease. In this study, we investigated by flow cytometry in different conditions (resting state, and after isolation and incubation, with and without stimuli) the expression pattern of several markers on PMN and monocytes, indicative of their maturation, capacity for chemotaxis, adhesion, opsonization, migration, and phagocytosis in 25 PAD patients, 12 healthy blood donors, and 4 septic patients. In this context, we also analyzed patients before and after the initiation of replacement treatment, as well as an untreated patient in different clinical conditions. Interestingly, we observed that PAD patients exhibit a chronic activation status of the innate immunity compartment, along with several differences in the expression of activation, maturation, and adhesion markers, with respect to different clinical conditions. Moreover, immunoglobulin replacement treatment had a favorable effect on PMN, as it was expressed by a more mature and less activated phenotype on basal state cells, and an enhanced activation capacity after LPS exposure. Thus, we conclude that PAD patients display a persistent innate immune cell activation, which is probably associated with the chronic inflammatory stress, usually observed in these disorders.
format Online
Article
Text
id pubmed-7695510
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76955102020-12-02 Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies Tsinti, Gerasimina Makris, Demosthenes Germenis, Anastasios E. Speletas, Matthaios J Immunol Res Research Article Primary antibody deficiencies (PAD) represent a heterogeneous group of disorders, with common variable immunodeficiency being the most common with clinical significance. The main phenotypic defect resides in the inability of B cells to produce antibodies, and the cornerstone of therapy is immunoglobulin replacement treatment in order to fight infections. However, the management of the other inflammatory manifestations is inadequate, reinforcing the hypothesis that a complex genetic background affecting additional cell populations, such as polymorphonuclear cells (PMN) and monocytes, influences the expression of the clinical phenotype of the disease. In this study, we investigated by flow cytometry in different conditions (resting state, and after isolation and incubation, with and without stimuli) the expression pattern of several markers on PMN and monocytes, indicative of their maturation, capacity for chemotaxis, adhesion, opsonization, migration, and phagocytosis in 25 PAD patients, 12 healthy blood donors, and 4 septic patients. In this context, we also analyzed patients before and after the initiation of replacement treatment, as well as an untreated patient in different clinical conditions. Interestingly, we observed that PAD patients exhibit a chronic activation status of the innate immunity compartment, along with several differences in the expression of activation, maturation, and adhesion markers, with respect to different clinical conditions. Moreover, immunoglobulin replacement treatment had a favorable effect on PMN, as it was expressed by a more mature and less activated phenotype on basal state cells, and an enhanced activation capacity after LPS exposure. Thus, we conclude that PAD patients display a persistent innate immune cell activation, which is probably associated with the chronic inflammatory stress, usually observed in these disorders. Hindawi 2020-11-20 /pmc/articles/PMC7695510/ /pubmed/33274244 http://dx.doi.org/10.1155/2020/8317671 Text en Copyright © 2020 Gerasimina Tsinti et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tsinti, Gerasimina
Makris, Demosthenes
Germenis, Anastasios E.
Speletas, Matthaios
Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title_full Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title_fullStr Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title_full_unstemmed Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title_short Persistent Activation of Innate Immunity in Patients with Primary Antibody Deficiencies
title_sort persistent activation of innate immunity in patients with primary antibody deficiencies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695510/
https://www.ncbi.nlm.nih.gov/pubmed/33274244
http://dx.doi.org/10.1155/2020/8317671
work_keys_str_mv AT tsintigerasimina persistentactivationofinnateimmunityinpatientswithprimaryantibodydeficiencies
AT makrisdemosthenes persistentactivationofinnateimmunityinpatientswithprimaryantibodydeficiencies
AT germenisanastasiose persistentactivationofinnateimmunityinpatientswithprimaryantibodydeficiencies
AT speletasmatthaios persistentactivationofinnateimmunityinpatientswithprimaryantibodydeficiencies